Axogen, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; the supplied text does not provide a separate, complete fourth-quarter income statement.
Business context
Axogen develops and sells products for peripheral nerve repair and regeneration, including Avance Nerve Graft and Axoguard products. The business is reported as one operating segment and derives substantially all revenue from U.S. customers. Avance accounted for approximately 60% of revenue. Axogen reported 1,006 active accounts and 376 core accounts at year-end.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $159.0 million | $138.6 million |
| Gross profit / margin | $127.9 million / 80.4% | $114.4 million / 82.6% |
| Operating loss | $21.5 million | $29.7 million |
| Net loss | $21.7 million | $28.9 million |
| Net loss per share | $0.51 | $0.69 |
| Cash used in operating activities | $5.7 million | $16.1 million |
- Revenue increased 14.7%; management attributed growth to unit volume (+8.6%), price (+3.7%) and product mix (+2.5%). Gross margin fell 2.2 percentage points.
- Research and development expense was $28.3 million, compared with $27.2 million. Sales and marketing expense rose to $86.1 million; general and administrative expense declined to $34.9 million.
- Cash and cash equivalents were $31.0 million at year-end, with $6.0 million restricted cash. Cash, cash equivalents and restricted cash totaled $37.0 million, versus $21.5 million a year earlier. Current assets exceeded current liabilities by $57.6 million.
- Operating cash outflow improved year over year. Investing activities provided $19.3 million, primarily reflecting investment maturities and lower capital spending; the APC Facility renovation remained a major investment. Financing activities provided $2.0 million.
- Credit Facility principal was $50.0 million, with $46.6 million reported as long-term debt net of discount and fees. The stated rate was 12.99% at year-end, plus revenue participation payments estimated to add about 1.5% annually. Principal maturities are in 2027 and 2028.
Material changes, outlook and risks
- Revenue growth and a smaller operating loss improved results, but gross margin declined and the company remained loss-making with negative operating cash flow.
- Axogen transferred Avance processing to its new Axogen Processing Center in 2023. The company says the facility has up to three times prior capacity; it expects capital spending to decline after renovation, but has not established that anticipated efficiencies will be achieved.
- Management believes cash, investments and product-sale proceeds will fund operations for at least 12 months from issuance of the financial statements. No specific financial guidance for revenue or earnings is stated in the supplied filing text.
- Management expected to complete the rolling Avance BLA submission in Q3 2024 and described potential approval around mid-2025. Avance was still distributed under FDA enforcement discretion and a transition plan; approval, timing and labeling are uncertain. Because Avance generates about 60% of revenue, a loss or restriction of market access is a major risk.
- Axogen planned to launch Avive+ in Q2 2024, subject to its regulatory pathway and manufacturing readiness. The company will not return the discontinued Avive product to market.
- Other key risks include reliance on Cook Biotech for Axoguard products and manufacturing, the announced acquisition of Cook Biotech by RTI Surgical, reimbursement and adoption uncertainty, tissue supply and quality requirements, and inflation and supplier disruption.
- The debt includes revenue-based payments, restrictive covenants and a make-whole provision. Axogen disclosed that the lender may interpret the make-whole calculation differently; under the alternative interpretation, management estimated payments of up to approximately $9 million on the first tranche and $4 million on the second at scheduled maturity, with larger amounts possible upon earlier prepayment.
- CEO Karen Zaderej planned to retire in January 2025, with the Board searching for a successor. The filing estimates related transition and separation payments of $3.2 million, subject to timing and agreement terms.
- Economic-development grants for the APC Facility carry job-creation conditions; the evaluation date was extended to December 31, 2024. Management said ordinary-course legal matters were not expected to have a material adverse effect, though outcomes are uncertain.
Important facts for investors to verify
- Progress against the Avance BLA timetable, FDA feedback, inspection readiness and any limits on continued distribution or future labeling.
- Whether Avive+ launched as planned and whether its regulatory classification and manufacturing arrangements remain viable.
- Cash use, working-capital needs, APC Facility spending and performance, and the company’s ability to fund operations beyond management’s stated 12-month horizon.
- The credit agreement’s effective cost, covenant compliance and resolution of the make-whole calculation dispute.
- Cook Biotech supply and distribution terms following its acquisition, including any minimum-purchase requirements or changes in service.
- Reimbursement developments, product adoption and the sustainability of revenue growth and gross margins.